New Delhi-Based Biotec to Produce 100 Million Sputnik V Vaccines Annuaaly
The Russian Direct Investment Fund (RDIF) and New Delhi-based Panacea Biotec, a leading vaccine and pharmaceutical producer in India, announced today a cooperation agreement to produce 100 million doses per year of the Sputnik V vaccine.
The increased production of Sputnik V at Panacea Biotec sites will facilitate the global supply of Sputnik V to international partners of RDIF.
Dr. Rajesh Jain, Managing Director of Panacea Biotec, commented in a press statement, “Panacea Biotec brings decades of vaccine manufacturing and distribution know-how to scale-up Sputnik V supplies. Panacea Biotec will produce Sputnik V in its internationally accredited facilities complying to strict GMP standards and prequalified by WHO.”
Panacea Biotec has a strong track record of supplying more than 10 billion doses of Polio vaccines and over 150 million doses of Innovative fully liquid Vaccines to National Governments, UN Agencies, etc. Panacea Biotec’s vaccine manufacturing facilities are pharmaceutical and sterile cytotoxic injectable facilities and USFDA approved.
Panacea Biotec launched the world’s first fully-liquid Hexavalent vaccine (DTwP-Hib-HepB-IPV), EasySixTM, in 2017.
To date, Sputnik V has been registered in 59 countries globally with a total population of over 1.5 billion people.
The efficacy of Sputnik V is 91.6%, as confirmed by the data published in the Lancet, one of the world's oldest and most respected medical journals. The vaccine is based on a proven and well-studied platform of human adenoviral vectors. It uses two different vectors for the two shots in the course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
Panacea Biotec is an innovation-led biotechnology company that focuses on the discovery, development, and commercialization of prescription medicines primarily, focusing on Vaccines, Diabetes, Transplant, Gastroenterology, and Oncology.